Dai ichi Life Insurance Company Ltd Has $766,000 Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Dai ichi Life Insurance Company Ltd reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 61.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,292 shares of the medical equipment provider’s stock after selling 10,000 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Zimmer Biomet were worth $766,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Naples Money Management LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $35,000. Activest Wealth Management lifted its stake in shares of Zimmer Biomet by 410.4% in the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 275 shares in the last quarter. Blue Trust Inc. increased its position in shares of Zimmer Biomet by 48.4% during the fourth quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 153 shares in the last quarter. Quent Capital LLC raised its holdings in shares of Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after acquiring an additional 92 shares during the last quarter. Finally, Ancora Advisors LLC lifted its position in Zimmer Biomet by 63.3% in the 3rd quarter. Ancora Advisors LLC now owns 570 shares of the medical equipment provider’s stock valued at $64,000 after acquiring an additional 221 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH traded up $0.56 during trading hours on Friday, hitting $116.41. The company’s stock had a trading volume of 1,084,246 shares, compared to its average volume of 1,315,878. The company has a market cap of $23.95 billion, a price-to-earnings ratio of 25.20, a PEG ratio of 2.09 and a beta of 1.03. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.80. The business has a 50 day simple moving average of $123.45 and a two-hundred day simple moving average of $121.51. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $147.50.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.07. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. Zimmer Biomet’s revenue was up 3.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.89 EPS. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date of this dividend is Wednesday, June 26th. Zimmer Biomet’s payout ratio is presently 20.78%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Barclays increased their target price on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a report on Monday, February 12th. Argus raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research report on Tuesday. Citigroup lifted their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Finally, StockNews.com lowered Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a report on Monday, February 19th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $134.40.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.